As communicated on January 21, 2020, CTS will implement the licensed Grifols Babesia test for samples received on April 20, at the Charlotte, Dallas, Phoenix, St. Louis and Tampa laboratories. Babesia is a selective pooled NAT test, required for all blood donations collected by May 2020, in 14 States and the District of Columbia. To help you understand the requirements, CTS will host a Babesia Implementation and Review webinar on March 3, 2020 at 11:00 am CST. If you are interested in attending, please contact your Customer Service Manager for invitation details.
At CTS, we understand the impact converting to the Ortho viral marker platform has on your operation...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
The CTS 2020 Annual Laboratory Survey is on its way to your email box. We would appreciate you takin...
CTS originally communicated that Tampa will convert from the current Grifols Ultrio Plus NAT triplex...
In response to the FDA guidance document for Babesia, CTS will implement the licensed Grifols ...
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm thi...